Shahbaz Malik, MD
Interventional Cardiology · Omaha, NENPI 1932450897
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $12,473 of the $16,804 with a category attached, or 74.2%. Medtronic accounts for 62.2% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $8,631, 4.4 times the $1,983 reported in 2019.
Across 107 payments — averaging $157.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Boston Scientific$3K
- Edwards Lifesciences$2K
- Cardiva Medical, Inc.$257
- Shockwave Medical, Inc$199
- Heartflow, Inc.$192
- plus $522 from 6 others
What the payments were for
- Travel & lodging$12,47374%
- Food & beverage$4,33126%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 57 | $10,457 |
| Boston Scientific | 16 | $2,860 |
| Edwards Lifesciences | 16 | $2,317 |
| Cardiva Medical, Inc. | 5 | $257 |
| Shockwave Medical, Inc | 2 | $199 |
| Heartflow, Inc. | 2 | $192 |
| Terumo Medical Corporation | 1 | $140 |
| Abbott | 4 | $120 |
| Smith+Nephew | 1 | $93 |
| Abiomed | 1 | $66 |
| Philips North America LLC | 1 | $64 |
| Gilead | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,804 in reported general payments places this provider in the 75th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 14 | $25,598 |
| JardianceEmpagliflozin | 14 | $16,524 |
| Repatha SureclickEvolocumab | 25 | $12,839 |
| Atorvastatin Calcium | 142 | $1,225 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 57 | $1,176 |
| Metoprolol Succinate | 78 | $1,136 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 12 | $826 |
| ClopidogrelClopidogrel Bisulfate | 83 | $583 |
| Metoprolol Tartrate | 66 | $373 |
| Losartan Potassium | 40 | $360 |
| Carvedilol | 41 | $343 |
| Amlodipine Besylate | 45 | $327 |
| Rosuvastatin Calcium | 24 | $292 |
| Spironolactone | 22 | $264 |
| Lisinopril | 41 | $238 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$541K
- Poonam VelagapudiOmaha$142K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- Scott CarolloOmaha$19K
- Toufik HaddadOmaha$14K
- Charles OlsonOmaha$12K
- Haysam AkkadOmaha$11K
- Ajaypaul SukhiOmaha$9K
- Filip OleszakOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.